ERBB2 and breast cancer: In the primary BC cohort (SMC-BCBS TMA), c-MET overexpression in HR+/HER2−, HR+/HER2+, HER2-enriched, and TNBC cases was 4.7%, 3.8%, 7.1%, and 13.6%, respectively.